Armata Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARMP NYSE American 2836 www.armatapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates - Sep 21st, 2026 5:00 am
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation - Sep 14th, 2026 7:34 am
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 - Sep 14th, 2026 5:00 am
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Sep 10th, 2026 5:00 am
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials - Sep 3rd, 2026 5:00 am
Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight - Aug 13th, 2026 8:31 am
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update - Aug 12th, 2026 2:05 pm
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? - Jul 21st, 2026 5:05 am
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 - Jul 20th, 2026 5:00 am
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia - Jul 13th, 2026 5:00 am
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 - Jun 23rd, 2026 5:00 am
Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy? - Jun 19th, 2026 12:18 pm
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - May 13th, 2026 2:30 pm
Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength - May 8th, 2026 3:01 pm
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 - May 7th, 2026 5:00 am
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" - May 4th, 2026 5:00 am
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - Mar 25th, 2026 2:05 pm
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - Mar 19th, 2026 5:00 am
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod - Mar 2nd, 2026 8:23 am